留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

身体形态指数与高血压靶器官损伤的关联性研究

李方塘 杨小利 陈瑞丹 杨永健

李方塘, 杨小利, 陈瑞丹, 杨永健. 身体形态指数与高血压靶器官损伤的关联性研究[J]. 协和医学杂志, 2022, 13(1): 82-88. doi: 10.12290/xhyxzz.2021-0332
引用本文: 李方塘, 杨小利, 陈瑞丹, 杨永健. 身体形态指数与高血压靶器官损伤的关联性研究[J]. 协和医学杂志, 2022, 13(1): 82-88. doi: 10.12290/xhyxzz.2021-0332
LI Fangtang, YANG Xiaoli, CHEN Ruidan, YANG Yongjian. Correlation between A Body Shape Index and Target Organ Injury of Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 82-88. doi: 10.12290/xhyxzz.2021-0332
Citation: LI Fangtang, YANG Xiaoli, CHEN Ruidan, YANG Yongjian. Correlation between A Body Shape Index and Target Organ Injury of Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 82-88. doi: 10.12290/xhyxzz.2021-0332

身体形态指数与高血压靶器官损伤的关联性研究

doi: 10.12290/xhyxzz.2021-0332
基金项目: 

国家自然科学基金面上项目 81873477

详细信息
    通讯作者:

    杨永健, E-mail:yangyongjian38@sina.com

  • 中图分类号: R543

Correlation between A Body Shape Index and Target Organ Injury of Hypertension

Funds: 

National Natural Science Foundation of China General Program 81873477

More Information
  • 摘要:   目的  探究身体形态指数(a body shape index, ABSI)与高血压靶器官损伤的关系。  方法  本研究为横断面调查,研究对象为2020年3月至2021年1月于陆军军医大学附属大坪医院心血管内科住院的高血压患者。采用ASBI三分位数法,将其分为低ASBI组、中ASBI组和高ASBI组。比较3组高血压靶器官损伤检出率差异。采用多因素Logistic回归分析ASBI与高血压靶器官损伤的相关性。  结果  共入选685例符合纳入和排除标准的高血压患者,其中存在靶器官损伤445例;低ASBI组(ABSI≤0.076)229例、中ASBI组(0.076<ABSI≤0.078)228例、高ASBI组(ABSI>0.078)228例。高ASBI组左心室肥厚检出率高于低ASBI组(27.63%比12.66%,P<0.001),颈动脉粥样硬化、肾功能损伤检出率高于中ASBI组(39.04%比26.32%,P=0.015;14.04%比5.26%,P=0.007)和低ASBI组(39.04%比25.76%,P=0.008;14.04%比2.62%,P<0.001)。多因素Logistic回归分析结果显示,以低ABSI为参照,高ABSI是高血压患者发生左心室肥厚(OR=2.08,95% CI: 1.24~3.50, P<0.001)、肾功能损伤(OR=6.47,95% CI: 2.53~16.54, P<0.001)的独立危险因素。  结论  ABSI升高与高血压患者肾功能损伤、左心室肥厚具有关联性。
    作者贡献:李方塘负责研究方案框架设计、临床数据收集、统计分析及论文撰写;杨小利负责研究方案设计与技术指导;陈瑞丹负责临床数据收集和统计分析;杨永健负责研究方案设计审核、协调工作计论文修订。
    利益冲突:所有作者均声明不存在利益冲突
  • 表  1  不同ABSI患者临床资料比较

    指标 低ASBI组(n=229) 中ASBI组(n=228) 高ASBI组(n=228) P
    男性[n(%)] 88(38.43) 122(53.51)* 174(76.32)*# <0.001
    年龄(x±s,岁) 61.02±10.35 62.25±10.26 64.70±10.16* 0.001
    吸烟史[n(%)] 43(18.78) 69(30.26) 93(40.79)* <0.001
    饮酒史[n(%)] 28(12.23) 35(15.35) 54(23.68)* 0.003
    血脂异常[n(%)] 42(18.34) 44(19.30) 47(20.61) 0.764
    住院期间用药[n(%)]
      血管紧张素转化酶抑制剂/血管紧张素受体拮抗剂 40(17.47) 40(17.47) 41(17.98) 0.988
      β受体阻滞剂 31(13.54) 39(17.11) 33(14.47) 0.542
      钙通道阻滞剂 46(20.09) 51(22.37) 49(21.49) 0.835
      他汀类药物 35(15.28) 32(14.04) 39(17.11) 0.660
    ABSI:身体形态指数;*与低ASBI组比较,P均<0.05;#与中ASBI组比较,P<0.001
    下载: 导出CSV

    表  2  不同ABSI患者高血压靶器官损伤检出率比较[n(%)]

    指标 低ASBI组(n=229) 中ASBI组(n=228) 高ASBI组(n=228) P
    左心室肥厚 29(12.66) 44(19.30) 63(27.63)* <0.001
    颈动脉粥样硬化 59(25.76) 60(26.32) 89(39.04)*# 0.002
    脑损伤 29(12.66) 30(13.16) 30(13.16) 0.984
    肾功能损伤 6(2.62) 12(5.26) 32(14.04)*# <0.001
    冠心病 87(37.99) 103(45.18) 102(44.74) 0.220
    ABSI:同表 1*与低ASBI组比较,P均<0.05;#与中ASBI组比较,P均<0.05
    下载: 导出CSV

    表  3  ABSI与高血压患者靶器官损伤关联性的多因素Logistic回归分析结果

    指标 分类变量(以低ABSI组为参照) 连续变量
    中ABSI组[OR(95% CI)] 高ABSI组[OR(95% CI)] OR(95% CI) P
    左心室肥厚 1.52(0.91~2.56) 2.08(1.24~3.50)* 1.44(1.11~1.85) 0.006
    颈动脉粥样硬化 0.83(0.54~1.29) 1.14(0.73~1.78) 1.08(0.86~1.35) 0.524
    脑损伤 0.95(0.54~1.69) 0.72(0.39~1.32) 0.85(0.63~1.15) 0.288
    肾功能损伤 2.15(0.79~5.87) 6.47(2.53~16.54)* 2.65(1.69~4.15) <0.001
    冠心病 1.10(0.74~1.64) 0.73(0.48~1.11) 0.86(0.69~1.06) 0.145
    ABSI:同表 1*与低ASBI组比较,P均<0.001
    下载: 导出CSV
  • [1] Rothman KJ. BMI-related errors in the measurement of obesity[J]. Int J Obes (Lond), 2008, 32: S56-S59. doi:  10.1038/ijo.2008.87
    [2] Messerli FH, Williams B, Ritz E. Essential hypertension[J]. Lancet, 2007, 370: 591-603. doi:  10.1016/S0140-6736(07)61299-9
    [3] Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)[J]. Lancet, 2017, 390: 2549-2558. doi:  10.1016/S0140-6736(17)32478-9
    [4] Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index[J]. PLoS One, 2012, 7: e39504. doi:  10.1371/journal.pone.0039504
    [5] Sato Y, Fujimoto S, Konta T, et al. Body shape index: Sex-specific differences in predictive power for all-cause mortality in the Japanese population[J]. PLoS One, 2017, 12: e0177779. doi:  10.1371/journal.pone.0177779
    [6] Cheung YB. "A Body Shape Index" in middle-age and older Indonesian population: scaling exponents and association with incident hypertension[J]. PLoS One, 2014, 9: e85421. doi:  10.1371/journal.pone.0085421
    [7] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24: 24-56. doi:  10.3969/j.issn.1007-5410.2019.01.002

    Writing Group of 2018 Chinese Guidelines for the Manage-ment of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, et al. 2018 Chinese guide-lines for the management of hypertension[J]. Zhongguo Xinxueguan Zazhi, 2019, 24: 24-56. doi:  10.3969/j.issn.1007-5410.2019.01.002
    [8] 吴雪怡, 马文君, 邹玉宝, 等. 血压昼夜节律与年轻高血压患者靶器官损伤的相关性[J]. 中国循环杂志, 2020, 35: 1103-1107. doi:  10.3969/j.issn.1000-3614.2020.11.009

    Wu XY, Ma WJ, Zou YB, et al. Association Between Blood Pressure Dipping Status and Target Organ Damage in Young Patients With Hypertension[J]. Zhongguo Xunhuan Zazhi, 2020, 35: 1103-1107. doi:  10.3969/j.issn.1000-3614.2020.11.009
    [9] Cai W, Lang M, Jiang X, et al. Correlation among high salt intake, blood pressure variability, and target organ damage in patients with essential hypertension: Study protocol clinical trial (SPIRIT compliant)[J]. Medicine (Baltimore), 2020, 99: e19548. doi:  10.1097/MD.0000000000019548
    [10] Gomez-Marcos MA, Gomez-Sanchez L, Patino-Alonso MC, et al. A body shape index and vascular structure and function in Spanish adults (MARK study): A cross-sectional study[J]. Medicine (Baltimore), 2018, 97: e13299. doi:  10.1097/MD.0000000000013299
    [11] Jänne PA, Ou SI, Kim DW, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2014, 15: 1433-1441. doi:  10.1016/S1470-2045(14)70461-9
    [12] 杨月欣, 张环美. 《中国居民膳食指南(2016)》简介[J]. 营养学报, 2016, 38: 209-217. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXX201603003.htm

    Yang YX, Zhang HM. Introduction to the Dietary Guidelines for Chinese Residents (2016)[J]. Yingyang Xuebao, 2016, 38: 209-217. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXX201603003.htm
    [13] 孙晓静, 林海燕, 李晓红. 37160例健康体检者血脂异常结果分析[J]. 山东医药, 2020, 60: 78-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202019021.htm

    Sun XJ, Lin HY, Li XH. Analysis of the results of dyslipidemia in 37160 healthy subjects[J]. Shandong Yiyao, 2020, 60: 78-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202019021.htm
    [14] 许顶立, 任昊. 高血压病肾脏损害的诊断与防治[J]. 中华心血管病杂志, 2004, 32: 98-100. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHXX200402034.htm

    Xu DL, Ren H. Diagnosis and prevention of renal damage in hypertension[J]. Zhonghua Xinxueguanbing Zazhi, 2004, 32: 98-100. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHXX200402034.htm
    [15] Chen TK, Estrella MM, Astor BC, et al. Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK)[J]. Nephrol Dial Transplant, 2015, 30: 1329-1335. doi:  10.1093/ndt/gfv037
    [16] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41: 407-477. doi:  10.1093/eurheartj/ehz425
    [17] Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: Results From the China Hypertension Survey, 2012—2015[J]. Circulation, 2018, 137: 2344-2356. doi:  10.1161/CIRCULATIONAHA.117.032380
    [18] Hall JE, do Carmo JM, da Silva AA, et al. Obesity, kidney dysfunction and hypertension: mechanistic links[J]. Nat Rev Nephrol, 2019, 15: 367-385.
    [19] Wang L, Wang H, Zhang B, et al. Elevated Fat Intake Increases Body Weight and the Risk of Overweight and Obesity among Chinese Adults: 1991—2015 Trends[J]. Nutrients, 2020, 12: 3272. doi:  10.3390/nu12113272
    [20] Hu L, Huang X, You C, et al. Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China[J]. PLoS One, 2017, 12: e0170238. doi:  10.1371/journal.pone.0170238
    [21] Bozorgmanesh M, Sardarinia M, Hajsheikholeslami F, et al. CVD-predictive performances of "a body shape index" versus simple anthropometric measures: Tehran lipid and glucose study[J]. Eur J Nutr, 2016, 55: 147-157. doi:  10.1007/s00394-015-0833-1
    [22] Bouchi R, Asakawa M, Ohara N, et al. Indirect measure of visceral adiposity 'A Body Shape Index' (ABSI) is associated with arterial stiffness in patients with type 2 diabetes[J]. BMJ Open Diabetes Res Care, 2016, 4: e000188. doi:  10.1136/bmjdrc-2015-000188
    [23] Dhana K, Kavousi M, Ikram MA, et al. Body shape index in comparison with other anthropometric measures in prediction of total and cause-specific mortality[J]. J Epidemiol Community Health, 2016, 70: 90-96. doi:  10.1136/jech-2014-205257
    [24] Bawadi H, Abouwatfa M, Alsaeed S, et al. Body Shape Index Is a Stronger Predictor of Diabetes[J]. Nutrients, 2019, 11: 1018. doi:  10.3390/nu11051018
    [25] Ji M, Zhang S, An R. Effectiveness of A Body Shape Index (ABSI) in predicting chronic diseases and mortality: a systematic review and meta-analysis[J]. Obes Rev, 2018, 19: 737-759. doi:  10.1111/obr.12666
    [26] Leone A, Vizzuso S, Brambilla P, et al. Evaluation of Different Adiposity Indices and Association with Metabolic Syndrome Risk in Obese Children: Is there a Winner?[J]. Int J Mol Sci, 2020, 21: 4083. doi:  10.3390/ijms21114083
    [27] Bertoli S, Leone A, Krakauer NY, et al. Association of Body Shape Index (ABSI) with cardio-metabolic risk factors: A cross-sectional study of 6081 Caucasian adults[J]. PLoS One, 2017, 12: e0185013. doi:  10.1371/journal.pone.0185013
    [28] Geraci G, Zammuto M, Gaetani R, et al. Relationship of a Body Shape Index and Body Roundness Index with carotid atherosclerosis in arterial hypertension[J]. Nutr Metab Cardiovasc Dis, 2019, 29: 822-829. doi:  10.1016/j.numecd.2019.04.013
    [29] Chang Y, Guo X, Li T, et al. A Body Shape Index and Body Roundness Index: Two New Body Indices to Identify left Ventricular Hypertrophy among Rural Populations in Northeast China[J]. Heart Lung Circ, 2016, 25: 358-364. doi:  10.1016/j.hlc.2015.08.009
    [30] Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism[J]. Circulation, 2006, 113: 898-918. doi:  10.1161/CIRCULATIONAHA.106.171016
    [31] Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk[J]. Arterioscler Thromb Vasc Biol, 2008, 28: 1039-1049. doi:  10.1161/ATVBAHA.107.159228
    [32] Pagé A, Dumesnil JG, Clavel MA, et al. Metabolic syndr-ome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin)[J]. J Am Coll Cardiol, 2010, 55: 1867-1874. doi:  10.1016/j.jacc.2009.11.083
    [33] Capoulade R, Clavel MA, Dumesnil JG, et al. Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial[J]. JACC Cardiovasc Imaging, 2013, 6: 165-174.
    [34] Kawarazaki W, Fujita T. The Role of Aldosterone in Obesity-Related Hypertension[J]. Am J Hypertens, 2016, 29: 415-423. doi:  10.1093/ajh/hpw003
    [35] Foster MC, Hwang SJ, Porter SA, et al. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study[J]. Hypertension, 2011, 58: 784-790. doi:  10.1161/HYPERTENSIONAHA.111.175315
    [36] Abete I, Arriola L, Etxezarreta N, et al. Association bet-ween different obesity measures and the risk of stroke in the EPIC Spanish cohort[J]. Eur J Nutr, 2015, 54: 365-375. doi:  10.1007/s00394-014-0716-x
    [37] Wang GL, Zhang R, Zhou YT, et al. Combined Effects of A Body Shape Index and Serum C-reactive Protein on Ischemic Stroke Incidence among Mongolians in China[J]. Biomed Environ Sci, 2019, 32: 169-176.
    [38] Wang F, Chen Y, Chang Y, et al. New anthropometric indices or old ones: which perform better in estimat-ing cardiovascular risks in Chinese adults[J]. BMC Cardiovasc Disord, 2018, 18: 14. doi:  10.1186/s12872-018-0754-z
  • 加载中
表(3)
计量
  • 文章访问数:  715
  • HTML全文浏览量:  177
  • PDF下载量:  135
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-04-14
  • 录用日期:  2021-06-09
  • 刊出日期:  2022-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!